Early results for a closely watched drug combination from AstraZeneca, for treating cancer, which also boosts the immune system suggest that it is promising. Although the limited patient numbers prove that the data is not conclusive, it has been said so.
This British drugmaker, which fended off around $118 billion takeover bid in May from Pfizer for talking up the cancer drug prospects, has high hopes that the combination of 2 experimental drugs named tremelimumab and MEDIA736 would definitely work well.
A range of doses is still being explored by the company and hence, time is being taken for testing drugs of lung cancer for yielding results. At the ESMO or the European Society For Medical Oncology, data on only two dozen patients was reported on Saturday.
Pascal Soriot, the Chief Executive had stated earlier that the ESMO numbers would be limited. Still, Scott Antonia, a researcher of the Moffitt Cancer Center in Florida stated that the early signals were quite encouraging, both for efficacy as well as for safety. He said that this looks quite promising.
Some more definitive results are expected later this year and there are also plans of starting a pivotal clinical trial with this combination this year end or the start of 2015.
When we talk about AstraZeneca’s combination, adverse effects were seen on 6 out of 24 lung cancer patients. As of now, 18 patients are assessed for efficacy and tumor shrinkage is seen in 5 of these 28 percent.
Latest posts by Anne-Marie Jackson (see all)
- A Trip And A Fall Led To The Discovery Of A 1 Million Years Old Fossil - Jul 21, 2017
- Giant Iceberg Breaks Free From Larsen C Ice Shelf - Jul 14, 2017
- EBLM J0555–57Ab Is The Smallest Star Ever Discovered Until Now - Jul 13, 2017